A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Active, not recruiting · Phase 3 · NCT06140836
Conditions: Carcinoma, Non-Small-Cell Lung
At a glance
- Research payments reported, 2025
- $17,890
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 190
About the trial
- Sponsor
- Bristol-Myers Squibb (with Zai Lab (Shanghai) Co., Ltd.)
- Tested
- Repotrectinib (drug), Crizotinib (drug)
- Dates
- Started 2023-12-21; completion 2027-03-15
- Results posted
- Not yet
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $17,890 in research payments for this study in 2025 (1 payments).
Products named: Augtyro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ggs Diagnostics Llc $17,890
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.